Yongxian Hu
机构：Zhejiang Chinese Medical University, Shanghai Liangyou (China), Immunité et Cancer, Cell Technology (China), Zhejiang Lab, Luye Pharma (China), Zhejiang Institute of Mechanical and Electrical Engineering, Zhejiang University-University of Edinburgh Institute, First Affiliated Hospital Zhejiang University, Zhejiang University
发表论文 110 篇 · 总被引 2281 次 · h-index 23
代表论文
- CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells (2025 · Cell Reports Medicine · 被引 45)
- Regulatable C-X-C chemokine receptor type 4 in iPSC-derived NK cells improves bone marrow chemotaxis and targeting resident tumor (2025 · Trends in biotechnology · 被引 9)
- Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia (2025 · Experimental Hematology and Oncology · 被引 9)
- Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result (2025 · Journal of Advanced Research · 被引 7)
- IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study (2025 · The Lancet Haematology · 被引 3)
- CAR T-Cell therapy in chronic myeloid leukemia patients with lymphoid blast crisis: A multicenter clinical analysis (2025 · Cancer Letters · 被引 2)